PharmaBlock Sciences Nanjing Inc Class A

PharmaBlock Sciences released its 2026 interim report, with net profit attributable to the parent company at 99.4449 million yuan, up 37.17% from the same period last year. The company's total operating revenue was 1.059 billion yuan, a year-on-year increase of 15.19%, marking two consecutive years of growth. Net cash inflow from operating activities was 192 million yuan, down 58.80% year-on-year. The company's latest asset-liability ratio is 15.19%, gross margin is 32.49%, ROE is 2.18%, and diluted earnings per share is 0.43 yuan.

PharmaBlock Sciences announced plans to distribute a cash dividend of 1 yuan per 10 shares, including tax, to all shareholders, with an estimated total payout of 23.3 million yuan. The company reported revenue of 1.059 billion yuan and net profit attributable to shareholders of 99.44 million yuan for the first half of 2026.